This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Oct;13(5):379-80.

doi: 10.1007/s11926-011-0196-4.

JAK inhibition in rheumatoid arthritis

Aarat M Patel¹, Daniel Lupash, Douglas Chew, Marc C Levesque, Larry W Moreland

Affiliations

PMID: 21728017
DOI: 10.1007/s11926-011-0196-4

Comment

JAK inhibition in rheumatoid arthritis

Aarat M Patel et al. Curr Rheumatol Rep. 2011 Oct.

. 2011 Oct;13(5):379-80.

doi: 10.1007/s11926-011-0196-4.

Authors

Aarat M Patel¹, Daniel Lupash, Douglas Chew, Marc C Levesque, Larry W Moreland

Affiliation

¹ Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA.

PMID: 21728017
DOI: 10.1007/s11926-011-0196-4

No abstract available

PubMed Disclaimer

Comment on

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. Kremer JM, et al. Arthritis Rheum. 2009 Jul;60(7):1895-905. doi: 10.1002/art.24567. Arthritis Rheum. 2009. PMID: 19565475 Clinical Trial.

References

1. Ann Rheum Dis. 2010 Feb;69(2):413-6 - PubMed
1. Best Pract Res Clin Rheumatol. 2010 Aug;24(4):513-26 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer